Business Context and Reporting Period
This Form 8-K is a current report filed by Artiva Biotherapeutics, Inc. on July 22, 2026. The filing addresses Item 8.01 (Other Events) regarding the scheduling of the Company's 2026 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is administrative in nature and contains no financial performance data.
Material Changes
There are no material financial changes reported. The primary event is the announcement that the 2026 Annual Meeting is scheduled for September 8, 2026. This date is more than 70 days after the one-year anniversary of the 2025 Annual Meeting, triggering specific notice requirements under the Company's Bylaws.
Guidance, Outlook, and Management Commentary
Management has established the following deadlines for stockholder actions regarding the Annual Meeting:
- Stockholder Proposals and Director Nominations: Notices must be received by the close of business on August 1, 2026.
- Rule 14a-8 Proposals: Proposals intended for inclusion in the proxy statement must also be received by the close of business on August 1, 2026.
- Submission Address: All notices must be directed to the Company Secretary at 5505 Morehouse Drive, Suite 100, San Diego, California 92121.
The filing does not contain forward-looking guidance on business operations, risks, or contingencies beyond the procedural requirements for the meeting.
Investor Verification Checklist
- Verify the exact date of the 2026 Annual Meeting (September 8, 2026).
- Confirm the August 1, 2026 deadline for submitting stockholder proposals and director nominations.
- Review the Company's amended and restated Bylaws for specific formatting requirements for notices.
- Check the Company's principal executive office address for physical mail submissions.